Evidence supporting the use of: Peptide
For the health condition: Dementia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Peptides have garnered interest in the context of dementia, particularly Alzheimer’s disease, due to their potential neuroprotective and cognitive-enhancing properties. Some peptides, such as cerebrolysin (a mixture of peptides and amino acids) and certain synthetic peptides designed to mimic neurotrophic factors, have been investigated for their effects on memory, neuroinflammation, and neuronal survival. Clinical studies—primarily conducted in Eastern Europe and Asia—have shown modest improvements in cognitive function and daily living activities in patients with mild to moderate dementia when treated with peptide preparations like cerebrolysin. However, these studies often suffer from small sample sizes, methodological limitations, and inconsistent results. Meta-analyses suggest a potential benefit, but the quality of evidence is generally considered low to moderate. Research into individual peptides, such as those targeting amyloid-beta aggregation or tau hyperphosphorylation (key pathological features of Alzheimer’s), is ongoing. While animal models have demonstrated some positive effects, translation to human clinical benefit remains unproven. As of now, no peptide-based therapy has received widespread regulatory approval specifically for the treatment of dementia in major Western countries. Therefore, while there is some scientific rationale and preliminary clinical evidence supporting the use of peptides in dementia, the overall strength of evidence is limited, and further large-scale, rigorously designed trials are necessary to confirm efficacy and safety.

More about Peptide
More about Dementia

Products containing Peptide

We currently have no products on Vitabase that contain this ingredient.